WallStreetZenWallStreetZen

NASDAQ: BOLT
Bolt Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BOLT

Based on 1 analyst offering 12 month price targets for Bolt Biotherapeutics Inc

Min Forecast
$7.00+31.33%
Avg Forecast
$7.00+31.33%
Max Forecast
$7.00+31.33%

Should I buy or sell BOLT stock?

Based on 1 analyst offering ratings for Bolt Biotherapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BOLT stock forecasts and price targets.

BOLT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-20

1 of 1

Forecast return on equity

Is BOLT forecast to generate an efficient return?

Company
-132.99%
Industry
250.86%
Market
228.7%
BOLT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BOLT forecast to generate an efficient return on assets?

Company
-65.62%
Industry
90.06%
BOLT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BOLT earnings per share forecast

What is BOLT's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$21.65
Avg 2 year Forecast
-$19.87
Avg 3 year Forecast
-$20.83

BOLT revenue forecast

What is BOLT's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$5.2M+0.75%
Avg 2 year Forecast
$2.4M-54.19%
Avg 3 year Forecast
$153.0k-97.05%
BOLT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BOLT revenue growth forecast

How is BOLT forecast to perform vs Biotechnology companies and vs the US market?

Company
-81.23%
Industry
97.96%
Market
25.83%
BOLT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BOLT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BOLT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BOLT$5.33$7.00+31.33%Buy
APVO$0.61N/AN/A
CURX$0.36N/AN/A
INAB$2.23N/AN/A
GRDX$2.98N/AN/A
View Top Biotech Stocks

Bolt Biotherapeutics Stock Forecast FAQ

Is Bolt Biotherapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BOLT) stock is to Buy BOLT stock.

Out of 1 analyst, 0 (0%) are recommending BOLT as a Strong Buy, 1 (100%) are recommending BOLT as a Buy, 0 (0%) are recommending BOLT as a Hold, 0 (0%) are recommending BOLT as a Sell, and 0 (0%) are recommending BOLT as a Strong Sell.

If you're new to stock investing, here's how to buy Bolt Biotherapeutics stock.

What is BOLT's earnings growth forecast for 2025-2027?

(NASDAQ: BOLT) Bolt Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.

Bolt Biotherapeutics's earnings in 2025 is -$42,681,000.On average, 7 Wall Street analysts forecast BOLT's earnings for 2025 to be -$41,554,938, with the lowest BOLT earnings forecast at -$44,524,505, and the highest BOLT earnings forecast at -$37,849,457. On average, 7 Wall Street analysts forecast BOLT's earnings for 2026 to be -$38,138,525, with the lowest BOLT earnings forecast at -$62,883,574, and the highest BOLT earnings forecast at -$24,245,419.

In 2027, BOLT is forecast to generate -$39,978,885 in earnings, with the lowest earnings forecast at -$74,489,666 and the highest earnings forecast at -$2,499,112.

What is BOLT's revenue growth forecast for 2025-2027?

(NASDAQ: BOLT) Bolt Biotherapeutics's forecast annual revenue growth rate of -81.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.83%.

Bolt Biotherapeutics's revenue in 2025 is $5,195,000.On average, 7 Wall Street analysts forecast BOLT's revenue for 2025 to be $10,046,354, with the lowest BOLT revenue forecast at $5,643,157, and the highest BOLT revenue forecast at $13,493,670. On average, 7 Wall Street analysts forecast BOLT's revenue for 2026 to be $4,568,270, with the lowest BOLT revenue forecast at $0, and the highest BOLT revenue forecast at $12,092,478.

In 2027, BOLT is forecast to generate $293,674 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $604,624.

What is BOLT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BOLT) forecast ROA is -65.62%, which is lower than the forecast US Biotechnology industry average of 90.06%.

What is BOLT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BOLT price target, the average BOLT price target is $7.00, with the highest BOLT stock price forecast at $7.00 and the lowest BOLT stock price forecast at $7.00.

The Wall Street analyst predicted that Bolt Biotherapeutics's share price could reach $7.00 by Oct 20, 2026. The average Bolt Biotherapeutics stock price prediction forecasts a potential upside of 31.33% from the current BOLT share price of $5.33.

What is BOLT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BOLT) Bolt Biotherapeutics's current Earnings Per Share (EPS) is -$22.18. On average, analysts forecast that BOLT's EPS will be -$21.65 for 2025, with the lowest EPS forecast at -$23.20, and the highest EPS forecast at -$19.72. On average, analysts forecast that BOLT's EPS will be -$19.87 for 2026, with the lowest EPS forecast at -$32.76, and the highest EPS forecast at -$12.63. In 2027, BOLT's EPS is forecast to hit -$20.83 (min: -$38.81, max: -$1.30).

What is BOLT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BOLT) forecast ROE is -132.99%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.